Theravance/Astellas' antibiotic Vibativ gets US approval
This article was originally published in Scrip
Theravance/Astellas' Vibativ (telavancin) has secured its first approval worldwide, after getting the nod from the US FDA for complicated skin and skin structure infections (cSSSI) caused by Gram-positive bacteria in adults. Astellas, which has the rights to sell the drug in the US, plans to make the antibacterial available by the fourth quarter of the year. The drug is likely to cost between $150-200 per day, said a Theravance spokesman.